Navigation Links
JDRF-funded studies show regular CGM use increases diabetes control for all age groups
Date:9/8/2009

NEW YORK, September 8, 2009 The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors six days per week or more rather than the age of patients, and that benefits continue well past the time when people with type 1 diabetes begin using the devices including experiencing fewer low blood sugar emergencies.

The findings of two studies from the major multi-center trial funded by the Juvenile Diabetes Research Foundation were published online by the journal Diabetes Care (available at http://care.diabetesjournals.org/papbyrecent.shtml). The first showed that regular use of CGM devices is the principal factor in achieving better diabetes control, rather than the age of people using the monitors, or other demographic, clinical, or psychosocial factors. The second showed that people using CGM to help manage their disease were able to sustain good diabetes control; and just as important, that continued strong control came while actually lowering the incidence of hypoglycemia dangerous low-blood-sugar incidents that can occur with tightly managed type1 diabetes.

"Based on these results and previous JDRF CGM trials published over the past 12 months, we know that these devices can help people get in control of their diabetes, help people already managing their disease maintain good control, and help people stay in control over an extended period of time, while lowering their risk for hypoglycemia," said Dr. William V. Tamborlane, of Yale University, a co-chair of the JDRF funded study.

Research has shown that good blood sugar control is a key factor in reducing the risk of the devastating long-term complications of the disease, such as blindness and kidney disease but that the fear of low blood
'/>"/>

Contact: Joana Casas
mcasas@jdrf.org
212-479-7560
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. JDRF-funded researchers discover proteins regulating human beta cell replication
2. JDRF-funded clinical trial demonstrates continuous glucose monitoring improves blood sugar control
3. PRS And EmSense Partner To Integrate Bio-Sensory Measures In Packaging Research Studies
4. T-STAR grant funds genetic studies on shrimp and papaya and endangered cycad rescue
5. UC Davis begins $2.8 million in studies of agricultural nitrogens impacts
6. Studies shed light on collapse of coral reefs
7. Two new studies on circadian rhythms
8. New early detection studies of lung cancer in non-smokers launched today
9. Scripps studies offer new picture of Lake Tahoes earthquake potential
10. Analysis finds strong match between molecular, fossil data in evolutionary studies
11. Peregrines PS-targeting antibodies highlighted in AACR Annual Meeting studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2015)... 2015 Research and Markets  ( http://www.researchandmarkets.com/research/xsgs2s/gesture ... "Gesture Recognition & Touchless Sensing Market by Technology ... Others), Product (Biometric & Sanitary Equipment) & by ... to their offering. The total gesture ... reach $ 23.55 Billion by 2020 at a ...
(Date:6/8/2015)... , June 8, 2015  The Secure ... their selection of Troy Potter of ... immediately. SIBA is a non-profit association that was ... policy, education and implementation of solutions that protect ... ...
(Date:6/4/2015)... the co-chairs of the Blue Ribbon Study Panel on Biodefense ... USA Today,s investigative report ... findings of lax safety standards and called on the federal ... "The state of oversight of ... Lieberman , former senator and co-chair of the Blue Ribbon ...
Breaking Biology News(10 mins):Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 4Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 5Biodefense Panel Expresses Grave Concerns over Findings at Nation's Research Labs 2Biodefense Panel Expresses Grave Concerns over Findings at Nation's Research Labs 3
... September 8, 2008For allergy sufferers, the choice all too ... curtains or anything that could trigger indoor allergens. ... with the launch of Clorox® Anywhere® Anti-Allergen Fabric Spray, ... fabric surfaces in the home. Clorox® Anywhere® ...
... Francis S. Collins, M.D., Ph.D., a physician-geneticist and ... with the new Inamori Ethics Prize from the Inamori ... Reserve University. Modeled after the Nobel and Kyoto ... Inamori Ethics Prize instead honors outstanding international ethical leaders. ...
... headed by Prof. Daniel Rosenfeld of the Institute of ... come up with a surprising finding to the disputed ... The conclusion: both can be true, depending on local ... is one with significant consequences in an era of ...
Cached Biology News:The Clorox Company's new indoor allergen product reduces common indoor allergens up to 90 percent 2Leader of Human Genome Project honored with the Inamori Ethics Prize 2Dirty air brings rain -- then again, maybe not 2Dirty air brings rain -- then again, maybe not 3
(Date:6/30/2015)... ... 30, 2015 , ... Cannavoices , Inc., a premier ... video and broadcast initiative. Produced by filmmakers, the multi-platform initiative aims to become ... cannabis stories ever assembled. , Cannavoices profiles Advocates, Patients, Entrepreneurs, Growers, Investors, ...
(Date:6/29/2015)... DIEGO , June 29, 2015 BioNano ... group of top research institutes, announced today that a ... Mount Sinai resulted in the creation of the first ... complementary single DNA molecule methods for sequencing and genome ... , provided the comprehensive analysis of the contiguous diploid ...
(Date:6/29/2015)... ... June 29, 2015 , ... The StampedeCon 2015 Big ... the fourth year in a row, will bring top technology professionals to St. Louis. ... the intersection of data and technology. The event is proudly sponsored by DataStax, Cisco, ...
(Date:6/26/2015)... Kan. , June 26, 2015 /PRNewswire/ ... PETX ), a pet therapeutics company focused ... innovative biopharmaceutical products for companion animals, today ... effectiveness study of capromorelin (AT-002), the company,s ... Capromorelin is a small molecule that mimics ...
Breaking Biology Technology:Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) today ... 2007 financial results after the NASDAQ Global Market ... Jack Lief, Arena,s,President and Chief Executive Officer, and ... Financial Officer, will host a conference call,at 5:00 ...
... Phase 3 Trials for Crohn,s Disease, Pouchitis and ... ... Ocera Therapeutics, a,biopharmaceutical company focused on the licensing, development and,commercialization ... liver diseases, has announced the completion of a,$35.5 million Series ...
... Osteotech, Inc.,(Nasdaq: OSTE ), a leader in ... today that total revenue for the year,ending December 31, ... for the year ended December 31, 2006. Revenue from ... for full year,2007, an increase of 15% over core ...
Cached Biology Technology:Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008 2Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008 3Ocera Therapeutics Closes $35.5 Million Series C Financing 2Ocera Therapeutics Closes $35.5 Million Series C Financing 3Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 2Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 3Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 4Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 5Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 6
Agarose for baculovirus plaque assays which allow optimal growth of plated insect cells....
BD BaculoGold Max-XP Insect Cell Medium 1 Liter...
Mycoplasma and virus tested...
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
Biology Products: